| Stock Name | 東陽光藥 |
|---|---|
| Stock Code | 06887 |
| Company Full Name | 東陽光藥 |
| Industry | Healthcare |
| Principal Activities | 一家綜合性製藥公司,從事藥物的研發、生產和商業化,專注於感染、慢病及腫瘤等治療領域。 |
| Listing Date | 2025-08-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省東莞市松山湖園區工業北路1號 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | hecpharm.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | 卓佳证券登记有限公司,香港金钟道89号力宝中心1座31楼3101-3103室 |
| A-Share/US Dual Listing | No |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | To be extracted |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | 576,656,047 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | To be extracted |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 盈利约人民币24.8百万元 |
| Period-End Cash Balance | 人民币1,920,200,000元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | Loading... |
|---|
| Chairman | 張英俊 |
|---|---|
| Company Secretary | 鄭程傑 |
| Major Shareholders & Holdings | 控股股東為張先生、郭女士、廣東東陽光科技等一組股東,緊隨上市後直接或間接控制本公司50.98%的投票權。 |
|---|


